Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR419 for Postherpetic Neuralgia
CTR20220853Phase 2Completed
- Sponsor
- Semrod Biotechnology
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sr419 in postherpetic neuralgia (PHN), sponsored by Semrod Biotechnology. Started May 2022; status: completed.
02
Drugs
sr419
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on CTR20220853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220853.